The known biochemical properties of PTEN‐deficient cells, both from preclinical models and analysis of the genetic make‐up of these tumors from patients, make PI3K pathway inhibition one of the most appealing approaches for the targeting of triple‐negative PTEN‐null breast cancers. This evidence concerns the gene PTEN and breast cancer.